Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

Key Points

• Wedbush raised Vor Biopharma’s price target to $27 from $18 while maintaining a neutral rating, implying roughly 21% upside from the stock’s $22.31 price.
• Analyst sentiment is broadly positive but mixed: MarketBeat reports a consensus rating of “Moderate Buy” and an average target of $43.38, while individual ratings range from sell to strong buy.
• Vor Biopharma reported a quarterly loss of $0.80 per share, missing the $0.69 consensus estimate. Institutional investors own 97.29% of the company, and analysts expect a full-year loss of $2.51 per share.

Vor Biopharma (NASDAQ:VOR - Get Free Report) had its price target hoisted by equities research analysts at Wedbush from $18.00 to $27.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the stock. Wedbush's price objective would suggest a potential upside of 21.02% from the company's current price.

A number of other equities research analysts have also weighed in on VOR. Wall Street Zen lowered shares of Vor Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group raised shares of Vor Biopharma to a "strong-buy" rating in a research report on Thursday, April 30th. Finally, Weiss Ratings raised shares of Vor Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $43.38.

Vor Biopharma Stock Performance

Shares of NASDAQ:VOR traded down $1.28 during trading on Wednesday, hitting $22.31. 439,610 shares of the company's stock were exchanged, compared to its average volume of 1,067,896. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $50.20. The business's 50-day simple moving average is $18.00 and its 200 day simple moving average is $15.88.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities research analysts forecast that Vor Biopharma will post -2.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new stake in shares of Vor Biopharma during the second quarter valued at approximately $1,799,000. Bank of America Corp DE boosted its position in Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock valued at $2,014,000 after buying an additional 112,496 shares during the last quarter. Irenic Capital Management LP bought a new position in Vor Biopharma during the 1st quarter valued at $583,000. Renaissance Technologies LLC acquired a new stake in shares of Vor Biopharma during the first quarter worth $2,298,000. Finally, Sei Investments Co. bought a new position in Vor Biopharma in the first quarter worth about $245,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source